Tenaya Therapeutics (TNYA) Non-Current Assets (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Non-Current Assets of $38.5 million for Q1 2026, down 22.15% year-over-year from $49.5 million in Q1 2025, and down 6.84% quarter-over-quarter from $41.3 million in Q4 2025.
Tenaya Therapeutics (TNYA) Non-Current Assets (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $38.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 22.15% year-over-year to $38.5 million; the TTM figure through Mar 2026 stood at $169.9 million (down 21.16% YoY), while the FY2025 annual figure was $41.3 million, down 21.36% from the prior year.
- Non-Current Assets for Q1 2026 stood at $38.5 million, down from $41.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $90.7 million in Q1 2023, with the low at $38.5 million in Q1 2026.
- The 5-year median for Non-Current Assets is $58.2 million (2024), against an average of $60.7 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 60.82% in 2022, then sank 38.05% in 2024.
- Tenaya Therapeutics' Non-Current Assets stood at $85.2 million in 2022, then tumbled by 30.82% to $58.9 million in 2023, then decreased by 10.81% to $52.6 million in 2024, then retreated by 21.36% to $41.3 million in 2025, then slipped by 6.84% to $38.5 million in 2026.
- Business Quant data shows TNYA's Non-Current Assets at $38.5 million in Q1 2026, $41.3 million in Q4 2025, and $43.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Tenaya Therapeutics | 151.26 Mn | 151.26 Mn | - | 7.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.53 Mn |
| Mar 31, 2026 | 38.51 Mn |
| Dec 31, 2025 | 41.34 Mn |
| Sep 30, 2025 | 43.74 Mn |
| Jun 30, 2025 | 46.28 Mn |
| Mar 31, 2025 | 49.47 Mn |
| Dec 31, 2024 | 52.57 Mn |
| Sep 30, 2024 | 55.25 Mn |
| Jun 30, 2024 | 58.16 Mn |
| Mar 31, 2024 | 56.20 Mn |
| Dec 31, 2023 | 58.93 Mn |
| Sep 30, 2023 | 66.57 Mn |
| Jun 30, 2023 | 81.85 Mn |
| Mar 31, 2023 | 90.71 Mn |
| Dec 31, 2022 | 85.19 Mn |
| Sep 30, 2022 | 69.24 Mn |
| Jun 30, 2022 | 70.24 Mn |
| Mar 31, 2022 | 67.72 Mn |
| Dec 31, 2021 | 58.83 Mn |
| Sep 30, 2021 | 46.97 Mn |